Financials · URGN

UroGen Pharma Ltd. (URGN) financials

For the twelve months ended Sep 30, 2026, UroGen Pharma Ltd. reported $250.25M of revenue and -$65.75M of net income.

Revenue, TTM
$250.25M
Revenue growth, YoY
+159.3%
Net income, TTM
-$65.75M
Net margin
-26.3%
Free cash flow, TTM
-$132.05M
Cash
$85.56M
Total debt
$189.35M
P/S
5.51
Market cap
$1.38B
Annual revenue$109.79M
FY2016FY2025
Annual net income-$153.49M
FY2016FY2025
Annual free cash flow-$162.73M
FY2016FY2025

URGN revenue and earnings growth

URGN revenueQ3 2026$89.00M

Quarter YoY
+223.9%
QoQ
+22.8%
FY YoY
+21.4%
5Y CAGR
+56.2%

URGN revenue was $89.00M in fiscal Q3 2026 (ended Sep 30, 2026), up 223.9% from a year earlier and up 22.8% from the prior quarter. For the full fiscal 2025 it was $109.79M, up 21.4% from fiscal 2024. Compound annual growth was +56.2% over 5 years. It rose in 6 of the last 9 fiscal years. Fiscal 2025 is the highest of the 10 fiscal years on file.

URGN net incomeQ3 2026-$1.46M

URGN net income was -$1.46M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$33.35M a year earlier. For the full fiscal 2025 it was -$153.49M, compared with -$126.87M in fiscal 2024.

URGN free cash flowQ3 2026-$15.27M

URGN free cash flow was -$15.27M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$42.36M a year earlier. For the full fiscal 2025 it was -$162.73M, compared with -$97.06M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$109.79M$90.40M$82.71M$64.36M$48.04M$11.80M$18.0K$1.13M$8.16M$17.53M
Cost of revenue$12.45M$8.88M$9.36M$7.65M$5.16M$1.01M-$1.80M$600.0K$28.0K
Gross profit$97.34M$81.52M$73.35M$56.70M$42.88M$10.79M$18.0K-$675.0K$7.56M$17.50M
Research and development$67.11M$57.15M$45.61M$52.91M$47.64M$47.31M$49.30M$36.93M$18.70M-
Selling, general and admin$155.10M$121.15M$93.27M$82.84M$87.53M$90.22M$60.20M$39.57M$8.81M$6.42M
Operating income-$124.86M-$96.78M-$65.54M-$79.04M-$92.29M-$126.74M-$109.48M-$77.18M-$19.95M$798.0K
Pre-tax income-$153.42M-$124.04M-$98.32M-$108.03M-$109.37M-$125.11M-$105.15M-$75.53M-$19.98M-$1.94M
Income tax$78.0K$2.83M$3.92M$1.75M$1.45M$3.37M-$125.0K$19.0K-
Net income-$153.49M-$126.87M-$102.24M-$109.78M-$110.82M-$128.48M-$105.15M-$75.66M-$20.00M-$1.94M
EPS, basic-$3.19-$2.96-$3.55-$4.81-$4.96-$5.90-$5.12-$4.80-$2.14-$1.91
EPS, diluted-----$4.96-$5.90-$5.12-$4.80-$2.14-$1.91
Diluted shares----22.3M21.8M20.5M15.8M9.7M2.3M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$110.75M$171.99M$95.00M$55.41M$44.36M$52.86M$49.69M$101.32M$37.00M$21.36M
Short-term investments$49.31M$110.67M$56.16M-----$36.00M-
Receivables$33.08M$20.30M$15.44M$12.70M$11.72M$7.05M---$83.0K
Inventory$16.46M$9.23M$5.67M$4.33M$4.83M$1.96M--$316.0K$105.0K
Current assets$186.02M$276.13M$169.19M$128.91M$114.39M$115.62M$148.63M$102.24M$74.47M$22.04M
Total assets$200.46M$285.71M$178.31M$135.62M$119.75M$122.00M$202.39M$103.56M$75.55M$23.06M
Current liabilities$46.42M$45.95M$31.21M$23.92M$22.38M$21.44M$19.48M$13.46M$7.04M$3.14M
Long-term debt$122.21M$121.73M$98.55M$97.54M$0-----
Total debt$122.21M$121.73M$98.55M$97.54M$0-----
Total liabilities$305.93M$294.51M$243.52M$224.98M$111.33M$25.65M$22.09M$13.46M$7.04M$6.75M
Shareholders' equity-$105.47M-$8.80M-$65.21M-$89.36M$8.41M$96.36M$180.30M$90.09M$68.52M$16.31M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow-$162.44M-$96.77M-$76.38M-$87.56M-$84.89M-$105.89M-$71.02M-$37.33M-$9.57M$4.19M
Capital expenditures$289.0K$295.0K$194.0K$254.0K$752.0K$1.22M$325.0K$560.0K$271.0K$695.0K
Free cash flow-$162.73M-$97.06M-$76.57M-$87.81M-$85.64M-$107.10M-$71.34M-$37.89M-$9.84M$3.49M
Investing cash flow$61.56M-$20.61M-$953.0K$1.06M$4.07M$93.24M-$145.59M$35.29M-$36.28M-$719.0K
Financing cash flow$39.92M$194.62M$116.93M$97.13M$72.32M$16.53M$165.25M$66.42M$61.59M-$9.0K
Stock-based compensation$11.96M$13.11M$9.34M$10.58M$23.11M$28.02M$29.97M$30.64M$6.30M$1.97M
Depreciation and amortization$307.0K$329.0K$802.0K$924.0K$831.0K$416.0K$300.0K$400.0K$200.0K$200.0K

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY21.4%9.3%28.5%34.0%307.2%65450.0%-98.4%-86.2%-53.5%-
Gross margin88.7%90.2%88.7%88.1%89.3%91.4%100.0%-59.8%92.6%99.8%
Operating margin-113.7%-107.1%-79.2%-122.8%-192.1%-1074.2%-608211.1%-6842.2%-244.5%4.6%
Net margin-139.8%-140.4%-123.6%-170.6%-230.7%-1088.9%-584144.4%-6707.2%-245.2%-11.1%
Free cash flow margin-148.2%-107.4%-92.6%-136.4%-178.3%-907.7%-396344.4%-3359.4%-120.6%19.9%
Return on equity-----1317.2%-133.3%-58.3%-84.0%-29.2%-11.9%
Return on assets-76.6%-44.4%-57.3%-80.9%-92.5%-105.3%-52.0%-73.1%-26.5%-8.4%
Current ratio4.016.015.425.395.115.397.637.5910.597.03
Debt to equity----0.00-----

Source: XBRL data UroGen Pharma Ltd. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

URGN peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
URGN$250.25M+159.3%-$65.75M-26.3%$1.38B
LLY$86.46B+45.5%$27.58B31.9%$1.35T
JNJ$99.33B+7.8%$16.09B16.2%$680.19B
ABBV$66.01B+10.7%$10.34B15.7%$520.65B
MRK$67.38B+4.9%$2.45B3.6%$356.13B
NVS$54.53B+8.4%$13.98B25.6%$305.69B
AZN$58.74B+8.6%$10.22B17.4%$285.36B
ABT$48.23B+10.0%$4.70B9.7%$186.10B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$184.18B

URGN FAQ

8 questions
  • What is URGN revenue?
    UroGen Pharma Ltd. (URGN) reported $250.25M of revenue for the twelve months ended Sep 30, 2026. That is up 159.3% from the year before. Revenue for fiscal 2025 was $109.79M.
  • Is URGN profitable?
    No. UroGen Pharma Ltd. reported a net loss of $65.75M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does URGN have?
    UroGen Pharma Ltd. reported $85.56M in cash and cash equivalents and $189.35M of debt on its most recent balance sheet in SEC filings.
  • How fast is URGN revenue growing?
    UroGen Pharma Ltd.'s revenue changed +21.4% in fiscal 2025, to $109.79M. Its compound annual growth rate was +56.2% over 5 years.
  • What is URGN gross margin?
    UroGen Pharma Ltd.'s gross profit was $228.75M on $250.25M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 91.4%.
  • What is URGN free cash flow?
    UroGen Pharma Ltd. generated -$132.05M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$131.85M less capital expenditures.
  • When did URGN last report financial results?
    The latest statements here come from UroGen Pharma Ltd.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
  • Where does this URGN financial data come from?
    Quantisnow builds these statements from the structured XBRL data UroGen Pharma Ltd. files with the SEC. It is provided for information only and is not investment advice.